Clarivate Plc (CLVT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Financial performance showed improvements in ACV and renewal rates, but revenue remained flat, and a net loss was reported. The Q&A highlighted innovation in AI and potential growth in IP, but management's unclear responses on long-term potential and AI's competitive edge raise concerns. Despite raised guidance, the flat revenue and net loss, coupled with market uncertainties, suggest a neutral sentiment. Given the mid-sized market cap, the stock is likely to see minor fluctuations, leading to a neutral prediction of -2% to 2%.
Key Financial Performance
Annual Contract Value (ACV) Improved to 1.6%, a 30 basis point sequential improvement, driven by 2% ACV growth across Academia & Government and Life Sciences & Health.
Renewal Rate Increased to 93%, up 100 basis points year-over-year, reflecting strong customer retention.
Free Cash Flow Generated $115 million year-to-date, supporting share repurchases and debt paydown.
Revenue (Q3 2025) $623 million, essentially flat compared to the prior year.
Net Loss (Q3 2025) $28 million, an improvement over the prior year due to higher foreign exchange gains and the absence of a noncash impairment charge recorded last year.
Adjusted Diluted EPS (Q3 2025) Flat sequentially at $0.18, with changes attributed to the divestiture of ScholarONE.
Operating Cash Flow (Q3 2025) $181 million, with changes driven by adjusted EBITDA and working capital.
Recurring Organic Revenue Growth (First 9 months of 2025) Improved to 0.6% compared to 0.1% last year.
Organic Revenue Mix Increased to 88%, up from 80% in 2024.
Year-to-Date Revenue (2025) $1.84 billion, a decline of more than $50 million compared to the prior year, driven by disposals and divestitures.
Year-to-Date Free Cash Flow (2025) $276 million, with changes driven by adjusted EBITDA impact and lower capital spending.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-powered solutions: Clarivate introduced 12 new products and AI-powered capabilities across its segments, including Web of Science Research Intelligence, AI agent, trademark opposition assistant, RiskMark, and regulatory functionality within Cortellis.
Life Sciences & Health: Launched DRG Commercial Analytics 360 for medtech and AI-powered regulatory assistant in Cortellis Regulatory Intelligence, enhancing decision-making and efficiency.
Intellectual Property: Introduced AI-powered product taxonomy in IPfolio and Derwent patent monitor for better patent management and risk mitigation.
Global Reach: Secured contracts with major institutions like the British Library, Canadian Research Knowledge Network, CAPES in Brazil, and University of Melbourne.
A&G Segment: Transitioned from transactional sales to subscription-based revenue, achieving a 93% subscription mix compared to 81% last year.
Value Creation Plan (VCP): Focused on growth, innovation, and operational efficiency, resulting in improved renewal rates (93%) and organic revenue mix (88%).
Cost Efficiency: Achieved cost savings through disposals and streamlined operations, reducing capital spending by $30 million.
Strategic Alternatives: Actively reviewing strategic alternatives with updates expected in Q4 2025.
Business Model Optimization: Exited A&G transactional book sales and life sciences real-world data reselling market to focus on core areas.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company faces challenges due to constraints on higher education research funding, particularly in the U.S., which could impact renewals and revenue from academic institutions.
Regulatory Hurdles: The company is navigating global regulatory requirements, which may pose challenges in managing compliance efficiently, despite the introduction of AI-powered regulatory tools.
Economic Uncertainties: Foreign exchange fluctuations have impacted financial results, with a weaker U.S. dollar providing a tailwind but also introducing unpredictability in revenue and profit margins.
Strategic Execution Risks: The company is undergoing significant transitions, including exiting transactional book sales and the life sciences real-world data reselling market, which could disrupt operations and revenue streams during the transition period.
Competitive Pressures: The company is investing heavily in AI and product innovation to maintain its competitive edge, but there is a risk that competitors may outpace these efforts or that the investments may not yield the expected returns.
Supply Chain Disruptions: No explicit mention of supply chain disruptions was noted in the transcript.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Annual Contract Value (ACV): Expected continued acceleration in ACV growth in Q4 2025, with organic ACV growth already at 1.6% year-to-date.
Recurring Organic Revenue Growth: Anticipated to remain in the upper half of the guidance range for 2025, with organic recurring revenue mix at 88% year-to-date.
Revenue Guidance: Raised to $2.44 billion at the midpoint of the new range for 2025, reflecting better-than-expected organic performance and slower-than-anticipated attrition in business disposals.
Adjusted EBITDA: Expected to reach the high end of the guidance range for 2025, with a profit margin of approximately 41%.
Free Cash Flow: Projected to be near the midpoint of the guidance range for 2025, with a conversion rate of approximately 34% of adjusted EBITDA.
AI and Product Innovation: Plans to accelerate AI innovation at scale, embedding AI across customer workflows and launching new AI-native solutions in 2026 to drive organic ACV and recurring revenue growth.
Operational Efficiency and Margin Expansion: Aiming to achieve through organization-wide AI adoption and cost efficiencies.
Strategic Disposals: Expected to lower revenue by approximately $90 million in 2025, with most of the remaining impact occurring in 2026.
Capital Allocation: Flexibility between share repurchases and deleveraging in Q4 2025.
2026 Focus: Continued execution of the value creation plan, rapid deployment of AI solutions, and operational excellence to drive innovation and shareholder value.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchases: Clarivate has executed $115 million of opportunistic share repurchases year-to-date. Additionally, during the third quarter, the company repurchased another 11.7 million shares, bringing the year-to-date buybacks to $150 million. This balanced capital deployment has allowed Clarivate to retire nearly $35 million or about 5% of its outstanding shares.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide insights into the competitive landscape of the patent renewal business and the recent pressures affecting it?
A:Jonathan Collins mentioned that the recurring order type is predominantly patents and trademark renewal services. Last year, this business declined by about 3%, but it is flat year-to-date, showing improvement. Investments in workflow software and market recovery are expected to drive growth. Matti Shem Tov added that changes in the IP segment, including new products like RiskMark and Derwent patent monitor, are expected to improve performance.
Q:Can you elaborate on the new innovations like Specto and AuthX AI Research Assistant and their impact on the business?
A:Matti Shem Tov highlighted that product innovation is a key part of their value creation plan. They are focusing on AI enablement of existing products to improve retention and competitiveness, as well as introducing AI-native products like RiskMark and Web of Science Research Intelligence. These innovations are expected to drive growth and improve customer collaboration.
Q:What was the impact of large book transactions on revenue and EBITDA, and what is the long-term potential of the business?
A:Jonathan Collins stated that without the large e-book transactions, disposals would have been down over $20 million in the quarter. These transactions are material for revenue but have low margins. Matti Shem Tov expressed confidence in the company's potential, aiming to achieve market growth rates of 3%-5% across segments over the next three years, supported by strong fundamentals, customer base, and talent.
Q:Which segments are driving ACV acceleration, and where is the largest room for improvement?
A:Jonathan Collins noted that all segments have contributed to ACV improvement, with the most notable progress in Life Sciences due to better retention and new sales. The IP segment has the most headroom for growth, supported by investments in products like Derwent patent search and IPMS software.
Q:What are the underlying trends in the IP market and catalysts for recovery in volumes?
A:Jonathan Collins explained that patents in force in core markets are growing, which is a positive indicator for the renewal business. The advent of AI is expected to drive innovation and lift patents in force in the coming years, contributing to market recovery.
Q:Can you clarify the role of AI in your offerings and the proprietary nature of your content?
A:Matti Shem Tov stated that many AI innovations support information services like Web of Science and Derwent Innovation. The company uses proprietary data collected, indexed, and presented to customers. While some AI automation is applied to workflow solutions, the majority focuses on information services.
Q:What is the impact of transactional revenues on guidance, and what are the expectations for next year?
A:Jonathan Collins mentioned that transactional revenues have improved guidance by $50 million, primarily due to slower-than-expected disposals and large transactions in Q3. The disposals will go to zero, with $90 million expected this year and over $100 million next year. FX and organic growth also contributed to the raised guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the long-term potential of the business, using general statements about strong fundamentals and market growth rates. Additionally, the response to the role of AI in offerings lacked clarity on the extent of proprietary content and its competitive advantage.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AG subscription
AI capability
AI product
AI solution
Agentic AI
Bioventus
China
Clarivate Conference
Health
Intelligence
Life Science
Research
Science platform
analytics
date
deployment
excellence
expertise
feature
improvement ACV
leader
library
medtech
model focus
momentum position
partner
petrochemical
plan result
portfolio
product AI
product patent
progress value
renewal rate
resource
result commitment
solution Web
subscription mix
support
team
testament
today Clarivate
tool
trademark
workflow
CLVT Transcript
Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call reveals strong financial improvements, such as a significant net loss reduction and increased EPS. AI product traction and efficiency benefits are well-received, with positive market positioning and growth in key segments. Despite some challenges in transactional revenues, the company's strategic shift towards subscription models and AI integration promises future growth. The Q&A section reinforces management's confidence and provides clarity on competitive positioning and market opportunities, particularly in China. Given the company's market cap, these factors suggest a positive stock price reaction in the near term.
Clarivate Plc (CLVT) Q4 2025 Earnings Call Transcript
Positive2-24
The company demonstrated strong financial performance with positive ACV growth, stable revenue retention, and improved EBITDA and cash flow. The Q&A highlighted optimism in AI product monetization and strategic synergies. Despite some unclear responses, the raised revenue guidance and focus on debt repayment over buybacks are seen as value-creating moves, suggesting a positive stock price movement.
Clarivate Plc (CLVT) Presents at Global Technology, Internet, Media & Telecommunications Conference 2025 Transcript
Neutral11-19
Clarivate Plc (CLVT) Q3 2025 Earnings Call Transcript
Unknown10-29
The earnings call presents a mixed outlook. Financial performance showed improvements in ACV and renewal rates, but revenue remained flat, and a net loss was reported. The Q&A highlighted innovation in AI and potential growth in IP, but management's unclear responses on long-term potential and AI's competitive edge raise concerns. Despite raised guidance, the flat revenue and net loss, coupled with market uncertainties, suggest a neutral sentiment. Given the mid-sized market cap, the stock is likely to see minor fluctuations, leading to a neutral prediction of -2% to 2%.
CLVT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
